Date | Price Target | Rating | Analyst |
---|---|---|---|
8/15/2024 | Overweight → Neutral | JP Morgan | |
12/11/2023 | Hold → Reduce | HSBC Securities | |
12/8/2023 | $3.00 → $7.00 | Underweight → Equal-Weight | Morgan Stanley |
10/17/2023 | Neutral | Cantor Fitzgerald | |
9/6/2023 | $4.21 | Buy | HSBC Securities |
7/19/2023 | $6.00 → $10.00 | Neutral → Buy | BofA Securities |
6/1/2023 | $7.00 → $8.00 | Equal Weight → Overweight | Barclays |
4/28/2023 | $7.00 | Overweight | JP Morgan |
On March 26, 2024, bluebird announced that it will restate its consolidated financial statements for the first three quarters and full-year 2022, as well as the first three quarters of 2023. As a result, the Company's Annual Report Form 10-K for 2023 and its Q1 2024 Form 10-Q have been delayed. Consistent with previous updates, the restatement is not expected to impact the Company's cash position or revenue. Sterling will transition to oversee the restatement process upon his start date.
Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume MRNA PUT SWEEP BULLISH 05/17/24 $122.00 $36.6K 148 2.3K ALNY PUT SWEEP BEARISH 07/19/
- 27 patient starts to date in 2024 (19 ZYNTEGLO, 4 LYFGENIA, 4 SKYSONA); anticipate approximately 85 patient starts across the portfolio as LYFGENIA patient starts accelerate in the second half of 2024 - - Second quarter 2024 net revenue of $16.1 million - - Cash runway into Q2 2025 based on current operating plans and cash on hand - - Management to host conference call today, August 14, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported second quarter results and business highlights for the quarter ended June 30, 2024, including recent commercial and operational progress. "We are seeing clear evidence that our commercial launch
bluebird bio, Inc. (NASDAQ:BLUE) announced today that it will host a conference call to discuss second quarter 2024 results and business updates on August 14, at 8:00 a.m. ET. To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and ask to be joined into the bluebird call or provide the Conference ID 2776050. To access the live webcast, please visit the "Events & Presentations" page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the event. About bluebird bio, Inc. bluebird bio is pursuing curative gene the
- First patient start (cell collection) for LYFGENIA completed – - 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the portfolio in 2024 - - First quarter 2024 net revenue of $18.6 million - - Management to host conference call today, May 9, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported first quarter results and business highlights for the quarter ended March 31, 2024, including recent commercial and operational progress. "bluebird has built a solid commercial gene therapy foundation, with an unparalleled network of qualified treatment centers (QTCs), proven
JP Morgan downgraded Bluebirdbio from Overweight to Neutral
HSBC Securities downgraded Bluebirdbio from Hold to Reduce
Morgan Stanley upgraded Bluebirdbio from Underweight to Equal-Weight and set a new price target of $7.00 from $3.00 previously
SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)
SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)
SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)
4 - bluebird bio, Inc. (0001293971) (Issuer)
4 - bluebird bio, Inc. (0001293971) (Issuer)
3 - bluebird bio, Inc. (0001293971) (Issuer)
bluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences: 2024 Wells Fargo Healthcare Conference, Wednesday, September 4, at 12:45 p.m. ET at the Encore Boston Harbor, Everett, MA Morgan Stanley 22nd Annual Global Healthcare Conference, Thursday, September 5, at 5:35 p.m. ET at the New York Marriott Marquis, New York, NY To access the live webcast of bluebird bio's fireside chats, please visit the "Events & Presentations" page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the
bluebird bio, Inc. (NASDAQ:BLUE) today announced that it received notices (the "notices") on August 20, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2024 (the "Q1 2024 Form 10-Q") and June 30, 2024 (the "Q2 2024 Form 10-Q"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). The notices have no immediate effect on the listing or trading of the Company's common stock on the Nasdaq. The Company p
- 27 patient starts to date in 2024 (19 ZYNTEGLO, 4 LYFGENIA, 4 SKYSONA); anticipate approximately 85 patient starts across the portfolio as LYFGENIA patient starts accelerate in the second half of 2024 - - Second quarter 2024 net revenue of $16.1 million - - Cash runway into Q2 2025 based on current operating plans and cash on hand - - Management to host conference call today, August 14, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported second quarter results and business highlights for the quarter ended June 30, 2024, including recent commercial and operational progress. "We are seeing clear evidence that our commercial launch
8-K - bluebird bio, Inc. (0001293971) (Filer)
8-K - bluebird bio, Inc. (0001293971) (Filer)
NT 10-Q - bluebird bio, Inc. (0001293971) (Filer)
For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali
For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing
CHICAGO, June 2, 2024 /PRNewswire/ -- 2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy. 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerDr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in th
bluebird bio, Inc. (NASDAQ:BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease. "We are thrilled to welcome James to bluebird bio. We are confident that his extensive experience in the healthcare sector and knowledge of the capital markets will position us well as we work to prove the commercial gene therapy model, and demonstrate progress on our path to profitability," said Andrew Obenshain, chief executive officer, bluebird bio. "It is an honor to be joining bluebird bi
Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh